logo
FDA: Popular Retailer Recalls Cheese Over Contamination Concerns

FDA: Popular Retailer Recalls Cheese Over Contamination Concerns

Yahoo26-03-2025

Aldi cheese is being recalled over metal fragment contamination.
It was made a Class II recall, which means consuming the product may cause serious adverse health concerns.
Below is more information about the recalled product.
Processed cheese can last a good bit of time in the fridge, which is why it's worth checking the back of yours for recently recalled Happy Farms by Aldi Colby Jack Finely Shredded Cheese. The product was recalled in February over potential foreign material contamination. Now, the U.S. Food and Drug Administration (FDA) is classifying it as a Class II recall, meaning that consumption could cause 'serious adverse health consequences.'
Four-hundred cases of the 12-ounce pouches of cheese were recalled in four states—Connecticut, Michigan, Ohio, and Pennsylvania—because they could potentially be contaminated with foreign matter—specifically, stainless steel fragments. The packages have the item number of 170374, the UPC code 4061463330840, and best-by dates of July 13, 2025 and July 14, 2025. If you believe you have affected product, do not eat it.
A press release announcing the recall was not published, so further details regarding how the cheese was contaminated are not available, nor are specific disposal or return instructions. However, according to Aldi's recall policy, the stores work to 'swiftly and effectively remove such products' from shelves. 'A 'pull-from-sale' alert from either the manufacturer of the suspect product or our own Corporate Buying Department will trigger a rapid response plan for handling recalls,' the grocer's site reads. 'Products that do not meet Aldi or government standards in any of these areas will be efficiently and effectively removed from sale.'
If you do still happen to have recalled product, reschedule taco night and follow the standard procedure for disposal and reaching out to either the store you purchased it from or the manufacturer, which, in this case, is Great Lakes Cheese Co Inc. The manufacturer can be reached at 440-834-2500 or via email at hello@greatlakescheese.com.
Other wellness and food products recently impacted by recalls include acne treatments, canned tuna, pancake mix, and more. A February report published by the Public Interest Research Group, a nonprofit consumer protection group, analyzed data from food recalls in 2024 and found that there were about 300 food recalls last year leading to nearly 1,400 illnesses associated with pathogens like salmonella, E. coli, and others.
Food safety experts attribute the apparent rise in numbers to a few causes, including a lack of proper sanitation practices and increased monitoring and reporting of these issues overall. 'We don't find outbreaks if we don't look for them,' Barbara Kowalcyk, Ph.D., associate professor and director of the Institute for Food Safety and Nutrition Security at George Washington University previously told Prevention. 'We're doing more investigations, but we also have better tools to do investigations with.' As a result, the U.S. may be experiencing more outbreaks and recalls than before, but the food supply is becoming more tightly regulated, she said.
You Might Also Like
Can Apple Cider Vinegar Lead to Weight Loss?
Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Dr. Pepper Is Being Recalled Right Now—Here's What to Know
Dr. Pepper Is Being Recalled Right Now—Here's What to Know

Yahoo

time35 minutes ago

  • Yahoo

Dr. Pepper Is Being Recalled Right Now—Here's What to Know

Over 19,000 cases of Dr. Pepper Zero Sugar are being recalled. This is because select cans of the 'zero sugar' product may contain sugar. The recalled soda was sold in three an ongoing recall on Dr. Pepper products, according to the Food & Drug Administration. This is due to mislabeling for their zero-sugar soda. The products impacted by this recall are Dr. Pepper Zero Sugar aluminum cans sold in 12- and 24-packs. Approximately 19,203 cases were affected and were sold at retail locations in Florida, Georgia and South Carolina. The recalled cases contain a production code of 'XXXXRS05165' and best-by date of February 16, 2026, printed on the packaging. Although the soda is labeled to be 'zero sugar,' the cans may contain the full-sugar product, thus the recall. The FDA just classified this recall as a Class II, meaning that the recalled product could cause 'temporary health consequences' if consumed. Check your Dr. Pepper Zero Sugar, and if it contains the recall information, dispose of it or return it to your place of purchase for a potential refund. For questions about this recall, call 1-888-INFO-FDA (1-888-463-6332). Read the original article on EATINGWELL

Zacks Industry Outlook Penumbra, Integer and AngioDynamics
Zacks Industry Outlook Penumbra, Integer and AngioDynamics

Yahoo

time44 minutes ago

  • Yahoo

Zacks Industry Outlook Penumbra, Integer and AngioDynamics

Chicago, IL – June 9, 2025 – Today, Zacks Equity Research discusses Penumbra PEN, Integer Holdings ITGR and AngioDynamics ANGO. Link: Over the past year, advancements in artificial intelligence (AI) and predictive analytics have rapidly revolutionized the Medical Instruments industry, driving innovation in diagnostics, patient monitoring and personalized treatment. AI-powered devices now process large datasets in real time, delivering accurate predictions and actionable insights. Predictive analytics supports early disease detection, risk assessment, maintenance optimization, and cost reduction. According to a January 2025 report, genAI is already generating synthetic medical images, simulating disease progression, and accelerating drug discovery. However, it also introduces new regulatory challenges around safety, transparency, and data integrity. In response, the FDA is implementing a Total Product Lifecycle (TPLC) oversight model with a risk-based approach and enhanced post-market monitoring. Going by data, global AI in the healthcare market is projected to witness a CAGR of 38.5% from 2024 to 2030. However, a deteriorating geopolitical situation, tariffs and supply chain bottlenecks, resulting in a tough situation related to raw material and labor costs, freight charges, as well as healthcare staffing shortages, have put the industry in a tight spot again. Meanwhile, industry players like Penumbra, Integer Holdings and AngioDynamics have adapted well to changing consumer preferences and have been witnessing an uptrend in their stock prices. The Zacks Medical - Instruments industry is highly fragmented, with participants engaged in research and development (R&D) in therapeutic areas. This FDA-regulated sector encompasses a vast array of products, from transcatheter valves and orthopedic devices to advanced imaging equipment and robotics. Recent trends highlight the integration of AI in diagnostics, the expansion of telemedicine, the rise of robotic-assisted surgeries, and developments in 3D printing, continuous glucose monitoring systems, gene editing, and nanomedicine. The emergence of generative AI is also reshaping MedTech, prompting the FDA to adopt a TPLC regulatory approach. Over the past couple of years, there has been a significant increase in the adoption of genAI within the medical instruments space, with "hyper-personalization" being the primary feature of genAI-driven treatment options. Added to this, genAI is rapidly paving the way for efficient operational management within the industry. GenAI, while analyzing vast and complex genetic and molecular data, is expected to help healthcare reach new heights in terms of predictive treatment options and smart hospital systems. A December 2024 report says that global genAI in the healthcare market was valued at $1.8 billion in 2023 and is expected to witness a CAGR of 33.2% from 2024 to 2032. Rapid advancement in deep learning and natural language processing, increasing demand for personalized treatment, growing investment in healthcare AI and rising healthcare data volumes are the major growth factors. This apart, the application of AI in the diagnostics space is growing enormously with the market expected to witness a CAGR of 24.6% by 2034. : The medical instruments space has been benefiting from the ongoing merger and acquisition (M&A) trend. It is a known fact that smaller and mid-sized industry players attempt to compete with the big shots through consolidation. The big players attempt to enter new markets through a niche product. Going by a J.P. Morgan report of 2025, in 2024, MedTech acquisition activity exceeded the previous two years in both deal count and total announced value. A total of 305 M&A transactions were announced, totaling over $63.1 billion for companies in medical devices, diagnostics, therapeutic digital health and commercial research tools, up from 134 deals in 2023. In 2025 so far, notable examples of M&A include Stryker's $4.9 billion acquisition of Inari Medical to expand its peripheral thrombectomy portfolio, Thermo Fisher's $4.1 billion purchase of Solventum's Purification & Filtration business, and Boston Scientific's $664 million acquisition of Bolt Medical to strengthen its position in intravascular lithotripsy solutions. : Per IMF's April 2025 World Economic Outlook, global growth is expected to remain lackluster over the next couple of years. At 2.8% in 2025 and 3.0% in 2026, the forecasts for growth are below the historical (2000–19) average of 3.7%. A few countries, especially low-income developing countries, have seen sizable downside growth revisions, often as a result of increased conflicts and recent tariff shocks. The good news is that global headline inflation is expected to decline to 4.3% in 2025 and to 3.6% in 2026, with advanced economies reaching the targets sooner than emerging market and developing economies. However, the IMF apprehends that the current policy-generated disruptions to the ongoing disinflation process could interrupt the pivot to easing monetary policy, with implications for fiscal sustainability and financial stability. Further, there are chances of higher nominal wage growth, which in some cases reflects the catch-up of real wages, accompanied by weak productivity, which could make it difficult for firms to moderate price increases, especially when profit margins are already squeezed. The Zacks Medical Instruments industry's Zacks Industry Rank, which is basically the average of the Zacks Rank of all the member stocks, indicates gloomy near-term prospects. The industry, housed within the broader Zacks Medical sector, currently carries a Zacks Industry Rank #131, which places it in the bottom 46% of 244 Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. We will present a few stocks that have the potential to outperform the market based on a strong earnings outlook. But it's worth taking a look at the industry's shareholder returns and current valuation first. The industry has underperformed the Zacks S&P 500 composite but outperformed the sector in the past year. The industry has declined 12.7% compared with the broader sector's decline of 14.7%. The S&P 500 has surged 12.8% in a year. On the basis of the forward 12-month price-to-earnings (P/E), which is commonly used for valuing medical stocks, the industry is currently trading at 29.04X compared with the broader industry's 19.18X and the S&P 500's 21.83X. Over the past five years, the industry has traded as high as 40.60X, as low as 25.62X and at the median of 32.52X. Integer Holdings: Plano, TX-based Integer Holdings is a medical device contract development and manufacturing organization. Its strategic focus on portfolio optimization, including the divestiture of its Non-Medical business, supports its long-term inorganic growth plans. Integer Holdings has established a solid position in the MedTech industry and continues to invest in research and product development, which bodes well for innovation and future revenue growth. The Zacks Consensus Estimate for this Zacks Rank #1 (Strong Buy) company's 2025 sales is pegged at $1.87 billion, indicating a 7.7% rise from 2024. The consensus mark for Integer Holdings' 2025 EPS is pegged at $6.33, indicating an increase of 19.4% from 2024. AngioDynamics: Headquartered in Latham, NY, AngioDynamics' solid prospects with NanoKnife and an increased focus on cancer treatment markets are encouraging. The company boasts a robust product pipeline and strong momentum in geographic expansion. Continued strong sales of Auryon, AlphaVac, and NanoKnife products further strengthen AngioDynamics' outlook. The consensus estimate for this Zacks Rank #1 company's fiscal 2026 sales is pegged at $305 million, indicating a 6.3% rise from fiscal 2025. The consensus mark for AngioDynamics' fiscal 2026 EPS is pegged at a loss of 24 cents, indicating an improvement of 14.9% from the year-ago period figure. Penumbra: Alameda, CA-based Penumbra's consistent revenue growth momentum is being driven by strong patient outcomes with Lightning Flash 2.0, Lightning Bolt 7 and RED 72. The company's vascular and neuro businesses are showing encouraging growth trends. Penumbra's Immersive Healthcare business too is making progress. The Zacks Consensus Estimate for Penumbra's 2025 sales is pegged at $1.35 billion, indicating a 13.4% rise from 2024. The consensus mark for Penumbra's 2025 EPS is pegged at $3.72, indicating an improvement of 67.6% from the year-ago period figure. Penumbra has a Zacks Rank #2 (Buy) currently. You can see the complete list of today's Zacks #1 Rank stocks here. Why Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Join us on Facebook: Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates. Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report Penumbra, Inc. (PEN) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio

Health-E Commerce® expands telehealth offerings with LifeMD™ to provide sleep treatments via FSA Store® and HSA Store®
Health-E Commerce® expands telehealth offerings with LifeMD™ to provide sleep treatments via FSA Store® and HSA Store®

Yahoo

time44 minutes ago

  • Yahoo

Health-E Commerce® expands telehealth offerings with LifeMD™ to provide sleep treatments via FSA Store® and HSA Store®

New collaboration delivers 50% off prescription sleep support for new customers who are struggling with insomnia and sleep disruption DALLAS, June 9, 2025 /PRNewswire/ -- Health-E Commerce, the parent brand of FSA Store and HSA Store, the first and leading online stores dedicated to selling only FSA- and HSA-eligible products and services, announced today that it has expanded its telehealth collaboration with LifeMD™, a leader in virtual care. This latest initiative gives FSA and HSA users affordable, convenient access to FDA-approved prescription sleep treatments at a time when better sleep care is urgently needed. According to the CDC, insufficient sleep is linked to higher risks of obesity, diabetes, heart disease, and depression, which means expanded access to treatment is not just beneficial, it's essential. The arrangement allows new customers who shop at FSA Store or HSA Store to receive 50% off prescription sleep medications from LifeMD, with no in-person appointments required. Following a free virtual consultation, approved patients can have non-addictive, physician-prescribed treatments discreetly delivered to their door, making it easier than ever to address sleep concerns with clinically backed solutions. "The connection between sleep and our overall physical and mental health is undeniable, and poor sleep can even impact our productivity at work and our overall quality of life," said Keri Kaiser, chief revenue officer for Health-E Commerce. "The expansion of our telehealth collaboration with LifeMD gives consumers more options for diagnosing and treating sleep disorders and improving sleep health, while saving money by using tax-free FSA- and HSA-eligible services. We're proud to simplify access to care for millions of Americans and to maximize their healthcare dollars." Many individuals who experience poor sleep rely on over-the-counter remedies that may not be effective for persistent insomnia or sleep disruptions. Fortunately, LifeMD's prescription sleep solutions are designed to address the root causes of poor sleep with medications that target sleep onset, duration, and quality, including Ramelteon, Doxepin, and Trazodone. Eligibility for prescription treatments is determined by a licensed LifeMD physician and backed by LifeMD's 4.9-star patient satisfaction rating. "We're proud to expand our telehealth collaboration with Health-E Commerce to give individuals and families who are enrolled in FSAs and HSAs access to clinical support to improve sleep health and their overall quality of life," said Nicholas Alvarez, co-founder and chief acquisition & growth officer at LifeMD. "Everyone deserves access to quality medical care that is convenient and affordable, and by collaborating with FSA Store and HSA Store, we are able to effectively extend the reach of our services to individuals and families across the country." LifeMD's sleep solutions are now available at and alongside other telehealth services for home sleep apnea testing, CPAP devices and supplies, CPAP alternatives, and more. This launch reinforces Health-E Commerce's mission to make tax-free healthcare dollars work harder for the more than 70 million Americans enrolled in pre-tax health accounts. To learn more or access eligible sleep health services and products, visit or About Health-E CommerceHealth-E Commerce is the parent brand to FSA Store and HSA Store, online stores that serve the 70+ million consumers enrolled in pre-tax health and wellness accounts. The company also created Caring Mill®, a popular private-label line of health products through which a portion of every purchase is donated to the Children's Health Fund. Since 2010, the Health-E Commerce brands have led the direct-to-consumer e-commerce market for exclusively pre-tax health and wellness benefits. Health-E Commerce plays an essential role in expanding eligibility for important new product and telehealth categories within the list of eligible medical expenses. About LifeMDLifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's health, weight management, and hormone therapy. The Company leverages a vertically-integrated, proprietary digital care platform, a 50-state affiliated medical group, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit View original content to download multimedia: SOURCE Health-E Commerce Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store